Izvestia learned about the immunological effectiveness of EpiVacCorona in 79%

The immunological efficacy of the EpiVacCorona CORONAVIRUS vaccine, created by the Vector State Scientific Center for Virology and Biotechnology, according to the results of interim trials, is 79%, follows from a review of the quality control of the third phase of clinical trials of the vaccine by an independent contract research organization - Clinical Research Laboratories (CRLab) , according to the newspaper "Izvestia".

So, on the 42nd day after vaccination with EpiVacCorona, IgG antibodies to covid-19 appeared in 79% of vaccinated volunteers and 11.6% of people who were given placebo.

As Tatyana Nepomnyashchikh, deputy HEAD of the Vector Center, explained, we are talking about the so-called immunological effectiveness of the vaccine. “It should not be confused with epidemiological effectiveness, which comes from other data and is calculated using a special formula. When they talk about the effectiveness of a vaccine, they mean precisely its epidemiological effectiveness,” Nepomnyashchikh explained.

Also, 96.9% of volunteers who were vaccinated with EpiVacCorona and 95.3% of those who received placebo did not have IgM antibodies that are produced during active COVID-19. This means that those vaccinated with EpiVacCorona will not infect anyone, the newspaper notes.